B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

CYP2E1

MOLECULAR TARGET

cytochrome P450 family 2 subfamily E member 1

UniProt: P05181NCBI Gene: 15714 compounds

CYP2E1 (cytochrome P450 family 2 subfamily E member 1) is targeted by 4 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting CYP2E1

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1ditiocarb2.4811
2Acetaminophen Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as0.691
3Acetaminophen Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as0.691
4Ditiocarb0.691

About CYP2E1 as a Drug Target

CYP2E1 (cytochrome P450 family 2 subfamily E member 1) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 4 compounds with documented CYP2E1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

CYP2E1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.